

18S Ribosomal DNA-Based PCR for Diagnosis of *Trichomonas vaginalis*

HOLGER MAYTA,¹ ROBERT H. GILMAN,^{1,2,3*} MARITZA M. CALDERON,¹ AREN GOTTLIEB,⁴
GISELLE SOTO,³ ISKRA TUERO,⁵ SIXTO SANCHEZ,⁶ AND ALDO VIVAR^{3,7}

Infectious Diseases Research Laboratory, Department of Pathology,¹ and Laboratory of Biochemistry, Department of Physiological Sciences,⁵ Universidad Peruana Cayetano Heredia, and A. B. PRISMA,³ Hospital Dos de Mayo,⁶ and Hospital Arzobispo Loayza,⁷ Lima, Peru; Department of Obstetrics and Gynecology, Mount Sinai School of Medicine, New York, New York⁴; and Department of International Health, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland²

Received 3 January 2000/Returned for modification 25 March 2000/Accepted 29 April 2000

***Trichomonas vaginalis* remains the most common sexually transmitted parasite in the world and is considered a major risk factor in the transmission of the human immunodeficiency virus. A PCR technique using primers targeting a specific region of the 18S rRNA gene of *T. vaginalis* was developed. The PCR test was standardized using 15 reference strains, giving a single product of 312 bp in all strains. No amplification was observed when DNA from related organisms or human DNA was used as a target. The test was evaluated on 372 vaginal swab specimens and 361 urine samples from women attending infertility and obstetric clinics at two separate hospitals in Lima, Peru. Compared to *T. vaginalis* culture, the overall sensitivity and specificity of PCR of vaginal swab samples was 100% and 98%, respectively. The PCR of urine samples was 100% sensitive and 99.7% specific compared to culture of vaginal swab, but the sensitivity drops to 83.3% when compared to PCR of vaginal swabs. All culture-positive samples were found to be positive by PCR in either urine or vaginal secretion. None of the PCR-negative samples were positive by culture. The origin of the amplification was confirmed by digestion of PCR products with *Hae*III. This PCR assay, which is easy to perform and has a high sensitivity and specificity, should be useful for routine diagnosis of *T. vaginalis* infection.**

Trichomoniasis is the most common parasitic sexually transmitted disease in the world (5, 8, 33). In addition to reproductive tract symptoms, infection with *Trichomonas vaginalis* is increasingly being recognized as having an association with reproductive complications including premature rupture of membranes, premature birth, low birth weight, and infections occurring after abortion and caesarean delivery (6). Even more important is its role as a risk factor for the transmission of the human immunodeficiency virus (11, 27).

As with other sexually transmitted diseases, symptoms and signs of trichomoniasis are not adequately sensitive or specific for diagnosis (32). Thus, diagnostic laboratory testing is usually required to confirm the presence of the organism. Routine clinical diagnosis usually depends on microscopic observation of motile parasites in wet-mount preparations. Although rapid and inexpensive, the wet mount may not be highly sensitive, especially when a delay in examining the sample occurs, detecting only about 60% of culture positive samples (10, 29). Culture is considered the most reliable method of diagnosis but requires a special medium and frequent microscopic observation for up to 7 days (12, 14, 20). The sensitivity of culture is less than 90%, allowing for false negatives due to lack of detection of nonviable or small numbers of parasites (3, 10, 25). Cytology preparations, such as Papanicolaou's stain test (Pap smear) (10, 19, 29), also lack both sensitivity and specificity. Other diagnostic techniques, such as monoclonal antibodies, in situ hybridization, and immunological assays, are

time-consuming and expensive and lack sensitivity (1, 10, 18, 23).

Several assays for the diagnosis of trichomoniasis based on PCR have recently been developed (9, 13, 22) and evaluated (15, 29, 30), the most common of which use DNA repetitive sequences as the target. This technique, however, allows for the production of nonspecific products due to the presence of insertion segments in some strains. Thus, different strains produce bands that migrate differently. In addition, repetitive sequences or amplification of the β -tubulin gene fails to detect some strains due to strain variation (15).

Recently, a comparative analysis of the 5.8S rRNA gene and the internal transcribed spacer regions of trichomonad protozoa demonstrated a high degree of intraspecies conservation of these sequences (2). Coding regions such as the 5.8S, 18S, and 28S genes are more conserved than the internal transcribed spacer regions. Ribosomal genes are highly conserved in their primary structure. This characteristic and their highly repetitive nature in the genome of most organisms make these genes good targets for detection by PCR. We have designed primers that are based on conserved regions of the 16S-like gene of *T. vaginalis*. In this study we determined the sensitivity and specificity of these primers using clinical samples from infertile and pregnant women in Lima, Peru.

MATERIALS AND METHODS

Strains. Fifteen *T. vaginalis* strains were isolated from Peruvian patients. Strains were grown in Diamond's modified TYM medium and axenized (14). These strains were used as reference strains to standardize the method.

Previously extracted DNA from *Trichomonas tenax* ATCC 30207, *Trichomonas gallinae* ATCC 30002, *Giardia lamblia* ATCC SF-741 30888, *Chilomastix sulcatus* ATCC 50562, *Dientamoeba fragilis* ATCC 30948, *Entamoeba histolytica* ATCC SF-31-90015, *Chlamydia trachomatis* serovar E ATCC VR3488, and *Neisseria gonorrhoeae* ATCC 19424 was used to assess the specificity of the PCR primers.

* Corresponding author. Mailing address: Department of International Health, Johns Hopkins University School of Hygiene and Public Health, 615 North Wolfe St., Baltimore, MD 21205. Phone: (410) 614-3959. Fax: (410) 614-5050. E-mail: Rgilman@jhsph.edu.

TABLE 1. Sample source, results of culture, PCR techniques, and kappa values for vaginal secretions tested for *T. vaginalis*

Hospital	Clinic ^a	No. of patients	No. (%) culture positive	No. (%) PCR positive (swabs)	Kappa
A. Loayza	Infertility	109	7 (6.4)	12 (11.0)	0.714
	Obstetric	179	8 (4.5)	9 (5.0)	
Dos de Mayo	Infertility	34	4 (11.8)	4 (11.8)	1.000
	Obstetric	50	5 (10.0)	6 (12.0)	
Total		372	24 (6.5)	31 (8.3)	0.868

^a No statistical differences were observed in incidence among patients from the different clinics ($P > 0.05$).

Sample collection. A total of 378 samples of vaginal secretions were obtained after informed consent from women attending the obstetric and infertility clinics of the Dos de Mayo and Arzobispo Loayza hospitals in Lima, Peru (Table 1). These two Ministry of Health public hospitals serve lower-middle-class populations of the city of Lima. The institutional ethics committees of Asociacion Benefica PRISMA and the Johns Hopkins University approved the protocol.

Two endocervical samples were collected from each woman using a sterile calcium alginate swab (Fisher Scientific, Pittsburgh, Pa.). One swab was placed in 3 ml of 0.15 M NaCl–0.05 M–Na₂HPO₄–NaH₂PO₄ (PBS, pH 7.2) plus antibiotics (penicillin G [200,000 U/ml], gentamicin [10 µg/ml], and amphotericin B [20 µg/ml]) and used for culturing. The other swab was placed in 500 µl of 0.01 M Tris-HCl (pH 8) and used for the PCR assay.

Patients were asked to collect urine specimens, which were kept at 4°C until they reached the laboratory, where they were processed immediately.

Culture. The PBS tube containing the vaginal swab was vortexed, the swab was discarded under sterile conditions, and the remaining liquid was centrifuged at 3,000 × *g* for 5 min. The supernatant was discarded, and the pellet was transferred into a tube containing 8 ml of Diamond's modified TYM (14). The tube was then incubated at 37°C for 8 days and observed microscopically every 2 days. The sample was considered negative if no motile trichomonads were observed in the culture medium after 10 days of incubation. Culture of a vaginal sample was used as the gold standard for PCR. Urine samples were not cultured.

DNA extraction of culture strains. Mid-log-phase axenic *T. vaginalis* cultures (10⁶ parasites/ml) were chilled on ice for 10 min and then pelleted by centrifugation at 3,000 × *g* for 5 min at 4°C. The cellular pellet was washed twice with PBS. DNA was then extracted according to a previously described procedure (23). Briefly, the cell pellet was resuspended in 1 ml of lysis buffer (450 mM NaCl, 15 mM sodium citrate, 0.2% sodium dodecyl sulfate) plus 200 µg of proteinase K per ml and incubated at 65°C for 1 h. DNA was then phenol-chloroform extracted, precipitated using ethanol and ammonium acetate, resuspended in 500 µl of buffer TE (0.01 M Tris-HCl, 0.001 M EDTA [pH 8]) containing 20 µg of DNase-free RNase per ml and incubated at 37°C for 30 min. The suspension was phenol-chloroform extracted, precipitated, and finally resuspended in 200 µl of DNase- and RNase-free water (Sigma, St. Louis, Mo.). The DNA concentration was spectrophotometrically determined (24).

Human DNA was extracted from leukocytes from a healthy volunteer using the QIAamp Tissue kit (Qiagen Inc., Chatsworth, Calif.). The DNA from *Toxoplasma gondii* strain RH was extracted using the same procedure.

DNA extraction from clinical samples. The Tris-HCl tube containing the swab was vortexed, and after removal of the swab, a 100-µl aliquot was transferred to a 1.5-ml tube and pelleted in a microcentrifuge at 12,000 × *g* for 15 min at room temperature. The supernatant was discarded, and the pellet was resuspended in 200 µl of a 5% (wt/vol) suspension of Chelex 100 (Sigma) in 0.01 M Tris-HCl buffer (pH 8). The suspension was gently vortexed and then incubated at 56°C for 45 min, during which time it was vortexed at 15-min intervals. The samples were then boiled for 10 min and centrifuged at 12,000 × *g* for 30 s. They were either used immediately or stored at –20°C. The supernatant (5 µl) was directly employed in a 25-µl total volume of PCR mix. The original tube was stored at –70°C to confirm positive samples.

Five milliliters of urine sample was centrifuged for 5 min at 3,500 × *g*; the sediment was washed twice with 0.01 M Tris-HCl (pH 8) buffer. The final sediment was resuspended in 500 µl of Tris-HCl buffer. An aliquot of 200 µl was processed as described above for vaginal swab samples.

Five milliliters of urine sample was centrifuged for 5 min at 3,500 × *g*; the sediment was washed twice with 0.01 M Tris-HCl (pH 8) buffer. The final sediment was resuspended in 500 µl of Tris-HCl buffer. An aliquot of 200 µl was processed as described above for vaginal swab samples.

Primers. A set of primers targeting conserved regions of the 18S ribosomal gene (16S-like ribosomal gene; GenBank accession number U17510) of *T. vaginalis* was designed. The sequences were selected from regions of the 18S ribosomal gene that differed from those of *Trichomonas tenax* (accession no. U37711) *Trichomonas foetus* (U17509) *Entamoeba gingivalis* (D28490), *Trypanosoma brucei* (AJ009149), *Candida albicans* (M60302), *Giardia lamblia* (U09492), and *Homo sapiens* (U13369). The primer sequences were as follows: Tv1, 5' TAA

TGG CAG AAT CTT TGG AG 3', and Tv2, 5' GAA CTT TAA CCG AAG GAC TTC 3'.

PCR. PCR was performed with a thermal cycler Gene Amp PCR system 2400 (Perkin-Elmer Cetus, Norwalk, Conn.). A standard PCR was carried out in a total volume of 25 µl. The master mix consisted of 1× PCR buffer (Gibco-BRL, Gaithersburg, Md.), 2.5 mM MgCl₂, 200 µM each of the four deoxynucleoside triphosphates, 0.4 µM each primer, and 0.025 U of *Taq* DNA polymerase (Perkin-Elmer Cetus) per ml. A total of 2.5 ng of DNA from cultured organisms was used per 25 µl of PCR mix. The amplification procedure included 3 min of denaturation at 94°C, followed by 40 cycles each consisting of 10 s of denaturation at 94°C, 45 s of annealing at 58°C, and 15 s of extension at 72°C. A final extension step at 72°C for 5 min was included. Included with each amplification cycle were a *T. vaginalis*-positive and -negative vaginal sample, a sample with DNA extracted from *T. vaginalis*, and a blank containing water.

Each clinical sample was tested twice by PCR. All PCR-positive samples were confirmed by a third amplification after preparing a new sample from the backup tube.

Determination of analytical sensitivity. Analytical sensitivity was performed using one clinical isolate of *T. vaginalis*. Twofold dilutions of the parasites were made until 1 organism per 25 µl of PCR mix was achieved. Dilutions were then processed using the Chelex technique as described above for clinical samples. With a similar purpose, *T. vaginalis* purified DNA was 10-fold diluted starting from 10 ng.

Clinical specificity determination. *Trichomonas tenax* is a trichomonad of the oral cavity that is the protozoan most closely related to *T. vaginalis*. To determine if the primer set Tv1 and Tv2 cross-reacted with *T. tenax*, the primers were tested using 58 human dental plaque samples obtained from volunteers attending the dental clinic at Universidad Peruana Cayetano Heredia.

Detection of PCR inhibitors. For each clinical sample, a PCR for the human β-globin gene was carried out as a control for the presence of inhibitors using primers PCO4 (accession no. A26623) and GH20 (A26624); if inhibition was observed, the sample was diluted 1:10 and 1:100 and tested again. Cycling parameters were as follows: 4 min at 95°C and 30 cycles each of 15 s at 94°C, 30 s at 55°C, and 30 s at 72°C.

Detection of PCR products. A 10-µl aliquot of PCR product was separated by horizontal gel electrophoresis at 50 V on a 2.0% agarose gel in Tris-acetate-EDTA buffer. Gels were stained with ethidium bromide (0.5 µg/ml; Sigma), and PCR amplifications were visualized using a UV light transilluminator. The size of the amplified product (312 bp) was determined by comparison with a commercial 100-bp DNA ladder (Gibco-BRL).

Restriction enzyme analysis. To confirm if PCR products were derived from the 18S RNA gene, all positive products were digested with the restriction enzyme *Hae*III. Then, 13.5 µl of the PCR product was digested in 1× enzyme buffer using 1 U of enzyme. Tubes containing the reaction mixture were incubated for 3 h at 37°C. Finally, 15 µl of the reaction mixture was separated by horizontal electrophoresis in 2.5% agarose, and gels were ethidium bromide stained and visualized as described above.

Statistical analysis. Sensitivity and specificity for PCR in vaginal samples or urine samples were calculated using as the gold standard vaginal swab samples that were culture positive in Diamond's modified TYM medium. Agreement between the culture of the vaginal sample for *T. vaginalis* and the PCR test of either the vaginal swab or urine samples was calculated using the kappa test. Differences in prevalence among samples from the different clinics were calculated using the chi-squared test. Statistical analysis was done using the SPSS 7.5 software (SPSS Inc., Chicago, Ill.).

RESULTS

All reference strains used to standardize the PCR gave a positive amplification of 312 bp, as expected. In all the reference strains, the origin of the PCR products was derived from the 18S ribosomal gene, since digestion of the PCR products with restriction enzyme *Hae*III yielded, as expected, two fragments, one of 101 bp and the other of 211 bp (Fig. 1).

No amplification was observed when DNA from *Trichomonas tenax* ATCC 30207, *Trichomonas gallinae* ATCC 30002, *Giardia lamblia* ATCC SF-741 30888, *Chilomastix sulcatus* ATCC 50562, *Dientamoeba fragilis* ATCC 30948, *Entamoeba histolytica* ATCC SF-31-90015, *Chlamydia trachomatis* serovar E ATCC VR3488, *Neisseria gonorrhoeae* ATCC 19424, *Toxoplasma gondii* strain RH, or human leukocyte DNA was tested.

The analytical sensitivity of the primer set Tv1 and Tv2 was 10 fg for purified *T. vaginalis* chromosomal DNA (Fig. 2). Using the Chelex 100 method, the detection limit of the test was 1 whole flagellated cell per 25 µl of PCR mixture.

Presence of inhibitors. Of 372 vaginal swabs, only 1 sample, which had a high content of blood, demonstrated significant




FIG. 1. Agarose gel electrophoresis of PCR products and REA. Lanes 1 and 2, amplification products of two strains of *T. vaginalis*. Lanes 3 and 4, REA of amplified products of two different strains of *T. vaginalis*. Lane 5, REA of amplified product of *T. tenax*. Lane 6, REA of PCR product performed using water as the sample. Lane M, 100-bp DNA ladder.

inhibition. This sample first gave a negative amplification when the PCR for β -globin was performed but became positive after being diluted 1:10 or 1:100. This sample also gave a false-negative result when tested directly for *T. vaginalis*, but a positive result was observed when the diluted sample was tested.

Clinical specificity. None of the 58 dental plaque samples gave a positive amplification when PCR was performed using primer set Tv1 and Tv2, although wet-mount examination revealed the presence of *T. tenax* in eight samples and *Entamoeba gingivalis* in 15 samples.

Clinical samples. In clinical vaginal swab samples, *T. vaginalis* was detected by PCR in 8.3% (31 of 372) of the samples, compared to 6.5% (24 of 372) detected by culture. All of the 24 isolates were detected by PCR in both vaginal secretions and urine (Table 1). When urine samples were tested for PCR, 6.9% (25 of 361) of the samples gave a positive amplification for *T. vaginalis*. One of the PCR-positive, culture-negative patients did not have her urine sample tested by PCR. One woman with a vaginal sample positive for *T. vaginalis* by PCR but negative by culture had a positive urine sample on testing by PCR.

There was a high degree of concordance between PCR and culture when vaginal samples were tested for the presence of




FIG. 2. PCR sensitivity based on *T. vaginalis* genomic DNA quantity, Lanes 1 to 7, 10 ng, 1 ng, 100 pg, 10 pg, 1 pg, 100 fg, and 10 fg, respectively. Lane 8, water control. Lane M, 100-bp DNA ladder.

TABLE 2. PCR results for vaginal and urine samples tested for *T. vaginalis*

Hospital	Clinic	No. (%) of PCR-positive vaginal swabs	No. of PCR-positive urine samples/no. tested (% positive) urine	Kappa
A. Loayza	Infertility	12 (11.0)	8/107 (7.5)	0.827
	Obstetric	9 (5.0)	8/176 (4.7)	0.938
Dos de Mayo	Infertility	4 (11.8)	4/31 (12.9)	0.839
	Obstetric	6 (12.0)	5/45 (11.1)	0.897
Total		31 (8.3)	25/361 (6.9)	0.902

^a One patient with a PCR-positive, culture-negative vaginal secretion was not tested by PCR for urine.

T. vaginalis (kappa = 0.86, $P < 0.001$) (Table 1). Similar high concordance was observed when PCR of urine samples was compared to the PCR results of vaginal specimens (kappa = 0.94, $P < 0.001$) (Table 2).

Using the culture results for *T. vaginalis* as a gold standard, the overall sensitivity and specificity of PCR for vaginal samples using primer set Tv1 and Tv2 were 100 and 98%, respectively (Table 2). The PCR for urine samples, considering vaginal culture as the gold standard, was 100% sensitive and 99.7% specific.

All culture-positive clinical samples gave a single 312-bp band on PCR. The same band was observed with samples that were only positive for *T. vaginalis* by PCR. In all PCR-positive samples, the origin of the PCR product was shown to be derived from the 18S ribosomal gene of *T. vaginalis*, since digestion of PCR products with *Hae*III gave two bands, one of 101 and the other of 211 bp.

The majority of *T. vaginalis* isolates came from the Dos de Mayo Hospital (Table 2), while the lowest prevalence was observed among patients attending the obstetric clinic at Arzobispo Loayza Hospital. There was no statistical difference in the prevalence of *T. vaginalis* infection detected among patients attending the two hospitals, nor was there a difference in prevalence in either hospital between patients attending the obstetric versus the infertility clinic ($P > 0.05$).

DISCUSSION

Detection of sexually transmitted diseases has become important in the present context of the global spread of the human immunodeficiency virus. In order to reduce obstetric and gynecological complications associated with *T. vaginalis* infection, early diagnosis and treatment is important. The PCR methodology we have developed is highly sensitive for the detection of *T. vaginalis*. It is unique in that it uses the 18S ribosomal gene as the target for the primers Tv1 and Tv2.

The specificity of the Tv1 and Tv2 primers for *T. vaginalis* was examined by testing dental plaque specimens that were positive on microscopy for *T. tenax*. No cross-reaction was observed. Although primer Tv1 is highly homologous to the DNA of *T. tenax*, no amplification was observed when DNA from this organism was used, probably because of the high specificity of the second primer, Tv2, and the high temperature used during the annealing step.

As demonstrated, no unusual media or buffers are needed to transport the samples. Tris-HCl was successfully used, making the PCR less expensive and easily accessible for routine diagnosis. Chelex 100 has been reported to be useful for PCR sample preparation (31). Although high levels of nucleases within the parasite have been reported (16, 21), Chelex 100 was able to extract the DNA of *T. vaginalis* without problems, as previously demonstrated (15). Chelex DNA extracts stored at

Downloaded from <http://jcm.asm.org/> on October 31, 2020 by guest

–20°C, however, did degenerate over time (H. Mayta, personal observation).

In this study, primers Tv1 and Tv2 were also able to detect *T. vaginalis* in urine samples. PCR of urine samples gave results comparable to those obtained by culturing vaginal specimens. In contrast, PCR of urine samples rarely detected *T. vaginalis* from patients who had *T. vaginalis* PCR-positive and culture-negative vaginal specimens. If all PCR-positive specimens are considered (whether culture positive or negative), then the sensitivity of the urine PCR was 80%. When urine is used to detect trichomonas infection in large-scale population samples, the decrease in urine PCR sensitivity needs to be taken into consideration.

Molecular techniques for the diagnosis of *T. vaginalis* have been previously reported but are not as sensitive or specific as the PCR we described in the present study. The use of a DNA probe (1, 17, 23) has the disadvantage of cross-reacting with DNA from *Pentatrichomonas hominis* and also being relatively insensitive, since its detection limit is 200 axenically cultivated protozoa. The first PCR described for *T. vaginalis* (22) has a similar sensitivity to culture (7, 28) and also misses some axenically cultivated strains (15). Targeting another repetitive sequence, Kegne et al. (9) could amplify one axenically cultivated parasite, but this PCR has not been tested under clinical conditions. A nested PCR and a colorimetric nested PCR also were described which used as their target a repetitive DNA sequence (13, 18, 26). Both PCR protocols produce nonspecific bands, which may cause false-positive results. Nested PCR techniques, although generally sensitive, have a higher cost, are more labor intensive and are also more prone to contamination than a simple PCR. More recently, a PCR based on the β -tubulin genes (15) was described. However, due to the high degree of variation among *T. vaginalis* strains, it lacks sensitivity since it misses some culture-positive strains. The β -tubulin gene PCR also lacks specificity, since it cross-reacts with *T. tenax*.

The PCR described here is highly sensitive. All culture-positive specimens were detected by PCR. This technique is also highly specific, as demonstrated by the lack of cross-reaction with the closely related trichomonad *T. tenax*. The high sensitivity of primer set Tv1 and Tv2 may permit the detection of small numbers of *T. vaginalis* organisms, which may not grow in culture. Moreover, culture of *T. vaginalis* may not be successful, since between 300 and 500 organisms are required to obtain a positive result (4). The PCR using primer set Tv1 and Tv2 was indeed reproducible and, as demonstrated by restriction enzyme analysis (REA), the product obtained from clinical samples was concordant with those obtained from *T. vaginalis* axenic strains. The PCR assay for the detection of *T. vaginalis* that we have designed is simple, easy to perform, and highly sensitive and specific. While it is optimal when using vaginal secretions, the test will perform, albeit at lower levels of sensitivity, with urine samples, permitting an easy and non-invasive method of specimen collection.

While culturing of samples takes at least 7 days, the PCR assay described here takes about 4 to 5 h from the time of sample collection until electrophoresis of enzyme-restricted PCR products. Restriction analysis of PCR products is not a necessary step after it has been performed once; thus, on a routine basis, PCR for the diagnosis of *T. vaginalis* can be performed within a 3-h period.

ACKNOWLEDGMENTS

We thank Diana Williams for her comments and Martin McCann, Daniel Roth, and Anna Culotta for their assistance with the manu-

script. We also thank Maria, Isaac, J. P. Cal, J. B. Phu, and D. Sara for their technical assistance.

This study was partially supported by an ITREID training grant from the NIH and the anonymous charitable RG + ER fund.

REFERENCES

- DeMeo, L. R., D. L. Draper, J. A. McGregor, D. F. Moore, C. R. Peter, P. S. Kapernick, and W. M. McCormack. 1996. Evaluation of a desoxyribonucleic acid probe for the detection of *Trichomonas vaginalis* in vaginal secretions. *Am. J. Obstet. Gynecol.* **174**:1339–1342.
- Felleisen, R. 1997. Comparative sequence analysis of 5.8S rRNA genes and internal transcribed spacers (ITS) regions of trichomonadid protozoa. *Parasitology* **115**:111–119.
- Foust, A. C., and S. J. Kraus. 1980. *Trichomonas vaginalis*: reevaluation of its clinical presentation and laboratory diagnosis. *J. Infect. Dis.* **141**:137–143.
- Garber, G. E., L. Sibau, R. Ma, E. M. Proctor, and W. R. Bowie. 1987. Cell culture compared with broth for detection of *Trichomonas vaginalis*. *J. Clin. Microbiol.* **25**:1275–1279.
- Graves, A., and W. A. Gardner. 1993. Pathogenicity of *Trichomonas vaginalis*. *Clin. Obstet. Gynecol.* **36**:145–152.
- Heine, P., and J. A. McGregor. 1993. *Trichomonas vaginalis*: a reemerging pathogen. *Clin. Obstet. Gynecol.* **36**:137–144.
- Heine, R. P., H. C. Weisenfeld, R. L. Sweet, and S. S. Witkin. 1997. Polymerase chain reaction analysis of distal vaginal specimens: a less invasive strategy for detection of *Trichomonas vaginalis*. *Clin. Infect. Dis.* **24**:985–987.
- Honigberg, B. M. (ed.). 1989. Trichomonads parasitic in humans, p. 311–324. Springer Verlag, New York, N.Y.
- Kengne, P., F. Veas, N. Vidal, J. Rey, and G. Cuny. 1994. *Trichomonas vaginalis*: repeated DNA target for highly sensitive and specific polymerase chain reaction diagnosis. *Cell. Mol. Biol.* **40**:819–831.
- Krieger, J. N., M. R. Tam, C. E. Stevens, I. O. Nielsen, J. H. Hale, N. B. Kiviat, and K. K. Holmes. 1988. Diagnosis of trichomoniasis: comparison of conventional wet-mount examinations with cytological studies, cultures and monoclonal antibody staining of direct specimens. *JAMA* **259**:1223–1227.
- Laga, M., A. Manoka, M. Kivuvu, B. Malele, M. Tuliza, N. Nzila, J. Goeman, F. Behets, V. Batter, M. Alary, W. L. Heyward, R. W. Rider, and P. Piot. 1993. Non ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in woman: results for a cohort study. *AIDS* **7**:95–102.
- Levi, M. H., J. Torres, C. Piña, and R. S. Klein. 1997. Comparison of the InPouch TV culture system and Diamond's modified medium for detection of *Trichomonas vaginalis*. *J. Clin. Microbiol.* **35**:3308–3310.
- Lin, P. R., M. F. Shaio, and J. Y. Liu. 1997. One-tube, nested-PCR assay for the detection of *Trichomonas vaginalis* in vaginal discharges. *Ann. Trop. Med. Parasitol.* **91**:61–65.
- Linstead, D. 1989. Cultivation, p. 91–111. In B. M. Honigberg (ed.), Trichomonads parasitic in humans. Springer Verlag, New York, N.Y.
- Madico, G., T. C. Quinn, A. Rompalo, K. T. Mackee, Jr., and C. A. Gaydos. 1998. Diagnosis of *Trichomonas vaginalis* infection by PCR using vaginal swab samples. *J. Clin. Microbiol.* **36**:3205–3210.
- Muller, M. 1973. Biochemical cytology of trichomonad flagellates. *J. Cell Biol.* **57**:453–474.
- Muresu, R., S. Rubino, P. Rizzu, A. Baldini, M. Colombo, and P. Cappuccinelli. 1994. A new method for identification of *Trichomonas vaginalis* by fluorescent DNA in situ hybridization. *J. Clin. Microbiol.* **32**:1018–1022.
- Paces, J., V. Urbánková, and P. Urbánek. 1992. Cloning and characterization of a repetitive DNA sequence specific for *Trichomonas vaginalis*. *Mol. Biochem. Parasitol.* **54**:247–256.
- Petersen, C. S., L. Carl, D. Alnor, U. Thomsen, and H. K. Thomsen. 1995. Ignored trichomonal infestation diagnosed by Papanicolaou smear. *Genitourin. Med.* **71**:257–258.
- Philip, A., P. Carter-Scott, and Rogers C. 1987. An agar culture technique to quantitate *Trichomonas vaginalis* from women. *J. Infect. Dis.* **155**:304–307.
- Riley, D. E., and J. N. Krieger. 1992. Rapid and practical isolation from *Trichomonas vaginalis* and other nuclease-rich protozoa. *Mol. Biochem. Parasitol.* **51**:161–164.
- Riley, D. E., M. C. Roberts, T. Takayama, and J. N. Krieger. 1992. Development of a polymerase chain reaction-based diagnosis of *Trichomonas vaginalis*. *J. Clin. Microbiol.* **30**:465–472.
- Rubino, S., R. Muresu, P. Rappelli, P. L. Fiori, P. Rizzu, G. Erre and P. Cappuccinelli. 1991. Molecular probe for identification of *Trichomonas vaginalis* DNA. *J. Clin. Microbiol.* **29**:702–706.
- Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Schmidt, G. P., L. C. Matney, A. A. Zaidi, and S. J. Kraus. 1989. Evaluation of six media for the growth of *Trichomonas vaginalis* from vaginal secretions. *J. Clin. Microbiol.* **27**:1230–1233.
- Shaio, M. F., P. R. Lin, and J. Y. Liu. 1997. Colorimetric one-tube nested PCR for detection of *Trichomonas vaginalis* in vaginal discharge. *J. Clin. Microbiol.* **35**:132–138.
- Sorvillo, F., and P. Kerndt. 1998. *Trichomonas vaginalis* and amplification of HIV-1 transmission. *Lancet* **351**:213–214.

28. **Tabrizi, Z. N., B. A. Paterson, C. K. Fairley, F. J. Bowde, and S. M. Garland.** 1998. Comparison of tampon and urine as self-administered methods of specimen collection in the detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis* in women. *Int. J. STD AIDS* **9**:347-349.
29. **Thomason, J. L., S. M. Gelbart, J. F. Sobun, M. B. Schulien, and P. R. Hamilton.** 1988. Comparison of four methods to detect *Trichomonas vaginalis*. *J. Clin. Microbiol.* **26**:1869-1870.
30. **Van Der Schee, C., A. Van Belkun, L. Zwijgers, E. Van Der Brugge, E. L. O'Neill, A. Luijendijk, T. Van Rijsoort-Vos, W. I. Van Der Meijden, H. Verbrugh, and H. J. F. Sluiter.** 1999. Improved diagnosis of *Trichomonas vaginalis* infection by PCR using vaginal swabs and urine specimens compared to diagnosis by wet mount microscopy, culture, and fluorescent staining. *J. Clin. Microbiol.* **37**:4127-4130.
31. **Walsh, P. S., D. A. Metzger, and R. Higuchi.** 1991. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. *Biotechniques* **10**:506-513.
32. **Wolner-Hanssen, P., J. N. Krieger, C. E. Stevens, N. B. Kiviat, L. Koutsky, C. Critchlow, T. DeRouen, S. Hillier, and K. K. Holmes.** 1989. Clinical manifestations of vaginal trichomoniasis. *JAMA* **261**:571-576.
33. **World Health Organization.** 1995. Global prevalence and incidence of selected curable sexually transmitted diseases: overview and estimates. World Health Organization, Geneva, Switzerland.